Online Treatment Tool for Patients: Key Information You Need to Know About Your HER2-Positive Early Breast Cancer Diagnosis

Download this PDF consultation checklist with useful questions for your oncologist about your new HER2-positive early breast cancer diagnosis. You can then enter the specific information about your cancer into our interactive treatment tool by answering a series of multiple choice questions to see treatment options chosen by 5 breast cancer experts.
Format: Adobe Acrobat (.pdf)
File Size: 137 KB
Released: March 19, 2019

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Produced in collaboration with
Grace Logo
This activity is supported by an educational grant from
Genentech

Related Content

In this slideset from Clinical Care Options (CCO) Nelson Chao, MD, MBA, discusses best practice strategies for prevention and prophylaxis of GVHD.

Released: December 2, 2020

CCO Conference Coverage of ASH 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD person default Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

Download this brief slideset on the rationale for using immunotherapy in the treatment of ES-SCLC, from Clinical Care Options (CCO)

Mark A. Socinski, MD Released: December 1, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue